{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:49:30Z","timestamp":1781729370454,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019266","name":"Korea Medical Device Development Fund","doi-asserted-by":"crossref","award":["9991006814"],"award-info":[{"award-number":["9991006814"]}],"id":[{"id":"10.13039\/100019266","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100019266","name":"Korea Medical Device Development Fund","doi-asserted-by":"crossref","award":["KMDF_PR_20200901_0141"],"award-info":[{"award-number":["KMDF_PR_20200901_0141"]}],"id":[{"id":"10.13039\/100019266","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Previous studies have reported conflicting results on the predictive role of the platelet-to-lymphocyte ratio (PLR) in detecting clinically significant prostate cancer (CSPCa) at the time of prostate biopsies. We explored the predictive value of pre-biopsy PLRs for CSPCa using our large-cohort database. Consecutive men with serum prostate-specific antigen (PSA) levels of\u2009\u2265\u20093.0\u00a0ng\/mL or abnormal digital rectal examination (DRE) findings and who underwent prostate biopsies were included in the study. There was no significant difference in the pre-biopsy PLR between men with benign disease, clinically insignificant prostate cancer (CISPCa), and CSPCa. Only the subset of CSPCa patients with serum PSA levels of\u2009&lt;\u200910\u00a0ng\/mL showed lower PLRs than those with benign disease or CISPCa. In the entire patient cohort, multivariate analyses revealed that older age, diabetes mellitus, DRE abnormalities, higher serum PSA levels, and smaller prostate volume were predictors of CSPCa. However, the pre-biopsy PLR was not a significant predictor of CSPCa at the prostate biopsy in the entire patient cohort or the subset of patients with serum PSA levels of\u2009&lt;\u200910\u00a0ng\/mL. In summary, the pre-biopsy PLR is not an independent predictor of CSPCa at the prostate biopsy, regardless of the serum PSA level.<\/jats:p>","DOI":"10.1038\/s41598-021-93637-3","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T10:02:44Z","timestamp":1625824964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Platelet-to-lymphocyte ratio is not a predictor of clinically significant prostate cancer at the prostate biopsy: A large cohort study"],"prefix":"10.1038","volume":"11","author":[{"given":"Jeong Woo","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwancheol","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"issue":"6","key":"93637_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"issue":"16","key":"93637_CR2","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMms1914228","volume":"382","author":"HG Welch","year":"2020","unstructured":"Welch, H. G. & Albertsen, P. C. Reconsidering prostate cancer mortality: The future of PSA screening. N. Engl. J. Med. 382(16), 1557\u20131563 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"93637_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","volume":"157","author":"VA Moyer","year":"2012","unstructured":"Moyer, V. A. & U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157(2), 120\u2013134 (2012).","journal-title":"Ann. Intern. Med."},{"issue":"13","key":"93637_CR4","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","volume":"360","author":"FH Schr\u00f6der","year":"2009","unstructured":"Schr\u00f6der, F. H. et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360(13), 1320\u20131328 (2009).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"93637_CR5","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.3390\/ijms20071637","volume":"20","author":"DF Osses","year":"2019","unstructured":"Osses, D. F., Roobol, M. J. & Schoots, I. G. Prediction medicine: Biomarkers, risk calculators and magnetic resonance imaging as risk stratification tools in prostate cancer diagnosis. Int. J. Mol. Sci. 20(7), 1637 (2019).","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"93637_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/RLU.0000000000002526","volume":"44","author":"CY Lin","year":"2019","unstructured":"Lin, C. Y., Lee, M. T., Lin, C. L. & Kao, C. H. Comparing the staging\/restaging performance of 68Ga-labeled prostate-specific membrane antigen and 18F-choline PET\/CT in prostate cancer: A systematic review and meta-analysis. Clin. Nucl. Med. 44(5), 365\u2013376 (2019).","journal-title":"Clin. Nucl. Med."},{"issue":"1","key":"93637_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1365-2559.2011.04033.x","volume":"60","author":"KS Sfanos","year":"2012","unstructured":"Sfanos, K. S. & De Marzo, A. M. Prostate cancer and inflammation: The evidence. Histopathology 60(1), 199\u2013215 (2012).","journal-title":"Histopathology"},{"issue":"7","key":"93637_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nrurol.2014.143","volume":"11","author":"L Vignozzi","year":"2014","unstructured":"Vignozzi, L. & Maggi, M. Prostate cancer: Intriguing data on inflammation and prostate cancer. Nat. Rev. Urol. 11(7), 369\u2013370 (2014).","journal-title":"Nat. Rev. Urol."},{"key":"93637_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-018-0719-4","volume":"19","author":"H Peng","year":"2019","unstructured":"Peng, H. & Luo, X. Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: A meta-analysis. Cancer Cell Int. 19, 1\u201318 (2019).","journal-title":"Cancer Cell Int."},{"key":"93637_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.576812","volume":"7","author":"G Li","year":"2020","unstructured":"Li, G., Shang, Z., Liu, Y., Yan, H. & Ou, T. The diagnostic values of pretreatment serum inflammation markers and lipoprotein in men with total prostate-specific antigen between 4 and 10 ng\/ml. Front. Med. (Lausanne) 7, 576812. https:\/\/doi.org\/10.3389\/fmed.2020.576812 (2020).","journal-title":"Front. Med. (Lausanne)"},{"key":"93637_CR11","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3889\/oamjms.2019.252","volume":"7","author":"KP Adhyatma","year":"2019","unstructured":"Adhyatma, K. P. & Warli, S. M. Diagnostic value of platelet-to-lymphocyte ratio in prostate cancer. Open Access Maced. J. Med. Sci. 7, 1093 (2019).","journal-title":"Open Access Maced. J. Med. Sci."},{"issue":"7","key":"93637_CR12","first-page":"11746","volume":"8","author":"F Li","year":"2015","unstructured":"Li, F., Hu, H., Gu, S., Chen, X. & Sun, Q. Platelet to lymphocyte ratio plays an important role in prostate cancer\u2019s diagnosis and prognosis. Int. J. Clin. Exp. Med. 8(7), 11746\u201311751 (2015).","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"2","key":"93637_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5152\/tud.2020.19203","volume":"46","author":"NP Murray","year":"2020","unstructured":"Murray, N. P., Fuentealba, C., Salazar, A. & Reyes, E. Platelet-to-lymphocyte ratio and systemic immune-inflammation index versus circulating prostate cells to predict significant prostate cancer at first biopsy. Turk. J. Urol. 46(2), 115\u2013122 (2020).","journal-title":"Turk. J. Urol."},{"issue":"15","key":"93637_CR14","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.7314\/APJCP.2015.16.15.6407","volume":"16","author":"OH Yuksel","year":"2015","unstructured":"Yuksel, O. H., Urkmez, A., Akan, S., Yldirim, C. & Verit, A. Predictive value of the platelet-to-lymphocyte ratio in diagnosis of prostate cancer. Asian Pac. J. Cancer Prev. 16(15), 6407\u20136412 (2015).","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"2","key":"93637_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/bju.13206","volume":"118","author":"J Park","year":"2016","unstructured":"Park, J. et al. Low testosterone level is an independent risk factor for high-grade prostate cancer detection at biopsy. BJU Int. 118(2), 230\u2013235 (2016).","journal-title":"BJU Int."},{"issue":"2","key":"93637_CR16","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein, J. I. et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am. J. Surg. Pathol. 40(2), 244\u2013252 (2016).","journal-title":"Am. J. Surg. Pathol."},{"issue":"6","key":"93637_CR17","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140(6), 883\u2013899 (2010).","journal-title":"Cell"},{"key":"93637_CR18","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1056\/NEJMra072739","volume":"358","author":"OJ Finn","year":"2008","unstructured":"Finn, O. J. Cancer immunology. N. Engl. J. Med. 358, 2704\u20132715 (2008).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"93637_CR19","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1158\/1055-9965.EPI-14-0146","volume":"23","author":"AJ Templeton","year":"2014","unstructured":"Templeton, A. J. et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: A systematic review and meta-analysis. Cancer Epidemiol. Biomark. Prev. 23(7), 1204\u20131212 (2014).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"34","key":"93637_CR20","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng, D. Y. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J. Clin. Oncol. 27(34), 5794\u20135799 (2009).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"93637_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrc3004","volume":"11","author":"LJ Gay","year":"2011","unstructured":"Gay, L. J. & Felding-Habermann, B. Contribution of platelets to tumour metastasis. Nat. Rev Cancer. 11(2), 123\u2013134 (2011).","journal-title":"Nat. Rev Cancer."},{"issue":"7203","key":"93637_CR22","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454(7203), 436\u2013444 (2008).","journal-title":"Nature"},{"key":"93637_CR23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ijsu.2018.11.020","volume":"60","author":"J Guo","year":"2018","unstructured":"Guo, J. et al. Prognostic role of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in prostate cancer: A meta-analysis of results from multivariate analysis. Int. J. Surg. 60, 216\u2013223 (2018).","journal-title":"Int. J. Surg."},{"key":"93637_CR24","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.juro.2017.11.120","volume":"99","author":"SR Vasavada","year":"2018","unstructured":"Vasavada, S. R., Dobbs, R. W., Kajdacsy-Balla, A. A., Abern, M. & Moreira, D. M. Inflammation on prostate needle biopsy is associated with lower prostate cancer risk: A meta-analysis. J. Urol. 99, 1174\u20131181 (2018).","journal-title":"J. Urol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93637-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93637-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93637-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T11:20:39Z","timestamp":1670066439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93637-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["93637"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-93637-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,9]]},"assertion":[{"value":"2 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14240"}}